MX2021005357A - Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. - Google Patents
Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.Info
- Publication number
- MX2021005357A MX2021005357A MX2021005357A MX2021005357A MX2021005357A MX 2021005357 A MX2021005357 A MX 2021005357A MX 2021005357 A MX2021005357 A MX 2021005357A MX 2021005357 A MX2021005357 A MX 2021005357A MX 2021005357 A MX2021005357 A MX 2021005357A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- stopsâ
- polymers
- transport inhibiting
- inhibiting oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Varias modalidades proporcionan polímeros STOPSMR que son oligonucleótidos que inhiben el transporte de antígeno S, procesos para elaborarlos y métodos para usarlos para tratar enfermedades y condiciones. En algunas modalidades los oligonucleótidos modificados STOPSMR incluyen una secuencia al menos parcialmente fosforotioatada de unidades A y C alternantes que tienen modificaciones como se describe en la presente descripción. La actividad antiviral independiente de la secuencia contra hepatitis B de modalidades de oligonucleótidos modificados STOPSMR, según se determinó por ensayo de secreción de HBsAg, es mayor que la de un compuesto de referencia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862757632P | 2018-11-08 | 2018-11-08 | |
US201962855323P | 2019-05-31 | 2019-05-31 | |
US201962907845P | 2019-09-30 | 2019-09-30 | |
PCT/US2019/060283 WO2020097342A1 (en) | 2018-11-08 | 2019-11-07 | S-antigen transport inhibiting oligonucleotide polymers and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005357A true MX2021005357A (es) | 2021-06-30 |
Family
ID=70551410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005357A MX2021005357A (es) | 2018-11-08 | 2019-11-07 | Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20200147124A1 (es) |
EP (1) | EP3853240A4 (es) |
JP (1) | JP2022512975A (es) |
KR (1) | KR20210090217A (es) |
CN (1) | CN113286803A (es) |
AU (1) | AU2019376079A1 (es) |
BR (1) | BR112021008539A2 (es) |
CA (1) | CA3117163A1 (es) |
CL (1) | CL2021001202A1 (es) |
CO (1) | CO2021005762A2 (es) |
IL (1) | IL282640A (es) |
MA (1) | MA53674A (es) |
MX (1) | MX2021005357A (es) |
PE (1) | PE20211783A1 (es) |
PH (1) | PH12021551007A1 (es) |
SG (1) | SG11202104636XA (es) |
TW (1) | TW202031267A (es) |
WO (1) | WO2020097342A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
CA3126947A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
CA3136603A1 (en) | 2019-04-17 | 2020-10-22 | Aligos Therapeutics, Inc. | Bicyclic and tricyclic compounds |
JP2022535735A (ja) | 2019-05-31 | 2022-08-10 | アリゴス セラピューティクス インコーポレイテッド | 修飾ギャップマーオリゴヌクレオチドおよび使用方法 |
EP3980406A4 (en) | 2019-06-06 | 2023-06-28 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
US20220281911A1 (en) * | 2019-08-19 | 2022-09-08 | Mina Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
US20220378920A1 (en) * | 2019-09-10 | 2022-12-01 | Daiichi Sankyo Company, Limited | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF |
WO2021119325A1 (en) * | 2019-12-12 | 2021-06-17 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
JP2023515664A (ja) | 2020-03-06 | 2023-04-13 | アリゴス セラピューティクス,インコーポレーテッド | 修飾された短い干渉核酸(siNA)分子およびそれらの使用 |
TW202219273A (zh) * | 2020-07-23 | 2022-05-16 | 瑞士商赫孚孟拉羅股份公司 | 靶向rna結合蛋白位點之寡核苷酸 |
AU2021318943A1 (en) * | 2020-07-27 | 2023-03-02 | Aligos Therapeutics, Inc. | HBV binding oligonucleotides and methods of use |
CA3195542A1 (en) | 2020-10-15 | 2022-04-21 | Aligos Therapeutics, Inc. | Bicyclic compounds |
CA3197470A1 (en) | 2020-10-21 | 2022-04-28 | Aligos Therapeutics, Inc. | Bicyclic compounds |
AU2021383758A1 (en) * | 2020-11-20 | 2023-06-15 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
EP4251625A1 (en) | 2020-11-24 | 2023-10-04 | Aligos Therapeutics, Inc. | Tricyclic compounds |
WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
WO2022162157A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
CA3204317A1 (en) * | 2021-01-30 | 2022-08-04 | Ahmad Ali MORTAZAVI | Conjugated oligonucleotide compounds, methods of making and uses thereof |
EP4175965B1 (en) * | 2021-01-30 | 2024-03-13 | E-Therapeutics plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2023281434A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Pharmaceuticals, Inc. | Use of oligonucleotides for individuals with renal impairment |
EP4402262A1 (en) | 2021-09-01 | 2024-07-24 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
KR20240053635A (ko) | 2021-09-08 | 2024-04-24 | 알리고스 테라퓨틱스 인코포레이티드 | 변형된 짧은 간섭 핵산 (sina) 분자 및 그의 용도 |
KR20240099159A (ko) | 2021-09-08 | 2024-06-28 | 알리고스 테라퓨틱스 인코포레이티드 | 변형된 짧은 간섭 핵산(sina) 분자 및 이의 용도 |
CN114230624A (zh) * | 2021-12-22 | 2022-03-25 | 上海兆维科技发展有限公司 | 一种核苷二聚体亚膦酰胺的合成方法 |
TW202345861A (zh) | 2022-03-17 | 2023-12-01 | 美商艾利格斯醫療公司 | 經修飾之間隔體寡聚物及其使用方法 |
WO2023222858A1 (en) * | 2022-05-18 | 2023-11-23 | F. Hoffmann-La Roche Ag | Improved oligonucleotides targeting rna binding protein sites |
CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
WO2006043521A1 (ja) * | 2004-10-19 | 2006-04-27 | Nippon Shinyaku Co., Ltd. | ホスホロチオエート結合を有する光学活性なオリゴ核酸化合物 |
AU2007211080B9 (en) * | 2006-01-27 | 2012-05-03 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
PL2605794T3 (pl) * | 2010-08-20 | 2017-01-31 | Replicor Inc. | Chelatowe kompleksy oligonukleotydów |
PL2849798T3 (pl) * | 2012-05-18 | 2021-10-18 | Replicor Inc. | Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu |
HRP20231400T1 (hr) * | 2014-07-10 | 2024-02-16 | Replicor Inc. | Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d |
CA3037042A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Biopharma, Inc. | Modified oligonucleotides and methods of use |
-
2019
- 2019-11-07 AU AU2019376079A patent/AU2019376079A1/en active Pending
- 2019-11-07 US US16/676,929 patent/US20200147124A1/en active Pending
- 2019-11-07 JP JP2021525122A patent/JP2022512975A/ja active Pending
- 2019-11-07 KR KR1020217017323A patent/KR20210090217A/ko unknown
- 2019-11-07 SG SG11202104636XA patent/SG11202104636XA/en unknown
- 2019-11-07 BR BR112021008539-4A patent/BR112021008539A2/pt unknown
- 2019-11-07 MA MA053674A patent/MA53674A/fr unknown
- 2019-11-07 MX MX2021005357A patent/MX2021005357A/es unknown
- 2019-11-07 CN CN201980088039.4A patent/CN113286803A/zh active Pending
- 2019-11-07 WO PCT/US2019/060283 patent/WO2020097342A1/en unknown
- 2019-11-07 EP EP19880948.5A patent/EP3853240A4/en active Pending
- 2019-11-07 CA CA3117163A patent/CA3117163A1/en active Pending
- 2019-11-07 PE PE2021000674A patent/PE20211783A1/es unknown
- 2019-11-08 TW TW108140604A patent/TW202031267A/zh unknown
-
2021
- 2021-04-26 IL IL282640A patent/IL282640A/en unknown
- 2021-04-30 CO CONC2021/0005762A patent/CO2021005762A2/es unknown
- 2021-05-03 PH PH12021551007A patent/PH12021551007A1/en unknown
- 2021-05-06 CL CL2021001202A patent/CL2021001202A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20211783A1 (es) | 2021-09-08 |
CN113286803A (zh) | 2021-08-20 |
WO2020097342A1 (en) | 2020-05-14 |
PH12021551007A1 (en) | 2021-10-04 |
JP2022512975A (ja) | 2022-02-07 |
CA3117163A1 (en) | 2020-05-14 |
TW202031267A (zh) | 2020-09-01 |
MA53674A (fr) | 2021-07-28 |
EP3853240A1 (en) | 2021-07-28 |
BR112021008539A2 (pt) | 2021-08-03 |
AU2019376079A1 (en) | 2021-05-27 |
SG11202104636XA (en) | 2021-06-29 |
US20200147124A1 (en) | 2020-05-14 |
EP3853240A4 (en) | 2022-11-30 |
KR20210090217A (ko) | 2021-07-19 |
IL282640A (en) | 2021-06-30 |
CO2021005762A2 (es) | 2021-07-30 |
CL2021001202A1 (es) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005357A (es) | Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. | |
PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
TW201613613A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NZ630890A (en) | Microrna compounds and methods for modulating mir-122 | |
EA201791417A1 (ru) | Супрессия гена гентингтина, индуцированная рнк-интерференцией | |
MX2017008184A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
PH12013502157B1 (en) | Modulation of hepatitis b virus (hbv) expression | |
MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
MX2020013278A (es) | Analogos de nucleotidos. | |
NZ607996A (en) | Substituted nucleotide analogs | |
NZ602618A (en) | Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders | |
NZ717921A (en) | Microrna compounds and methods for modulating mir-21 activity | |
MD20170014A2 (ro) | Metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
IL274363B2 (en) | Use of a specific siRNA against protein S for the treatment of hemophilia | |
MX2020013551A (es) | Combinaciones farmaceuticas. | |
EA202190964A1 (ru) | Олигонуклеотидные полимеры и способы для ингибирования транспорта s-антигена | |
MX2018013885A (es) | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). | |
MX2019006886A (es) | Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). | |
MX2020002110A (es) | Composiciones y metodos para detectar y tratar la resistencia a la insulina. | |
IN2013DE01960A (es) | ||
RU2014144094A (ru) | Способы воздействия на экспрессию гена CREBBP | |
RU2014143385A (ru) | Способы воздействия на экспрессию гена TP53 | |
RU2014142755A (ru) | Способы воздействия на экспрессию гена CYP17 | |
RU2014144093A (ru) | Способы воздействия на экспрессию гена CRE | |
RU2014142756A (ru) | Способы воздействия на экспрессию гена D4DR |